Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Chemed Corporation (NYSE:CHE - Free Report) by 113.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,009 shares of the company's stock after purchasing an additional 10,635 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned about 0.14% of Chemed worth $8,561,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in CHE. Geneos Wealth Management Inc. grew its holdings in Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock valued at $61,000 after purchasing an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Chemed by 67.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company's stock valued at $5,534,000 after purchasing an additional 4,560 shares during the last quarter. Marshall Wace LLP bought a new position in Chemed during the 2nd quarter valued at about $579,000. Brown Advisory Inc. grew its holdings in Chemed by 36.9% during the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company's stock valued at $267,000 after purchasing an additional 148 shares during the last quarter. Finally, Cerity Partners LLC grew its holdings in Chemed by 237.7% during the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company's stock valued at $2,165,000 after purchasing an additional 3,133 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.
Chemed Price Performance
NYSE CHE opened at $427.85 on Wednesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85. The firm's 50 day moving average price is $398.34 and its 200-day moving average price is $425.88. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $583.96. The company has a market cap of $5.68 billion, a PE ratio of 23.32, a P/E/G ratio of 1.60 and a beta of 0.54.
Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm had revenue of $657.51 million for the quarter, compared to the consensus estimate of $659.22 million. During the same period last year, the firm earned $5.63 earnings per share. The company's quarterly revenue was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Sell-side analysts forecast that Chemed Corporation will post 22.3 EPS for the current fiscal year.
Chemed Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 13th. Stockholders of record on Monday, February 23rd were paid a dividend of $0.60 per share. The ex-dividend date was Monday, February 23rd. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. Chemed's dividend payout ratio (DPR) is currently 13.08%.
Insider Activity
In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.33% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the stock. Zacks Research upgraded shares of Chemed from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Chemed from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, April 29th. Royal Bank Of Canada upped their target price on shares of Chemed from $422.00 to $436.00 and gave the stock a "sector perform" rating in a research note on Monday, April 27th. Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Oppenheimer dropped their target price on shares of Chemed from $580.00 to $500.00 and set an "outperform" rating on the stock in a research note on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $501.50.
Check Out Our Latest Research Report on CHE
Chemed Profile
(
Free Report)
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
See Also
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.